Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus HALDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus HALDOL.
CHLORPROMAZINE HYDROCHLORIDE vs HALDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonizes dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histamine H1, muscarinic, and serotonin receptors.
Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia. It also has moderate affinity for sigma receptors and weak affinity for serotonin 5-HT2, alpha-adrenergic, and histamine H1 receptors.
25-100 mg orally or intramuscularly every 4-6 hours; maximum 2 g/day orally or 1 g/day intramuscularly.
Initial: 1-5 mg PO/IM twice daily; titrate up to 5-10 mg/day. Acute agitation: 5-10 mg IM every 1-8 hours. Maintenance: 5-10 mg/day PO/IM. Maximum: 100 mg/day.
None Documented
None Documented
Terminal elimination half-life 30 ± 14 hours (range 20–70 hours); clinical context: requires multiple daily dosing in acute agitation, but long-acting IM formulations (not chlorpromazine) available; half-life increases with age and hepatic impairment.
Terminal elimination half-life is approximately 21 hours (range 12–37 hours). Extended half-life in chronic administration supports once-daily dosing; dose adjustments required in hepatic impairment.
Primarily hepatic metabolism; renal excretion accounts for ~20% as unchanged drug and metabolites, with ~6% unchanged; biliary/fecal excretion ~80%, mainly as metabolites.
Renal (approximately 40%, with 1% unchanged; remainder as metabolites) and fecal (approximately 60%, primarily via bile).
Category C
Category C
Antipsychotic
Antipsychotic